Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: a phase 2 clinical trial

Lorusso, D.; Oaknin, A.; Borges, G.S.; Damian, F.; Ottevanger, N.; Gorp, T. van; ... ; Colombo, N. (2025)

Article / Letter to editor

Objective.

To estimate the clinical benefit of cemiplimab+peltopepimut-S vaccine after disease progression on first-line chemotherapy.

Methods.

This global phase 2 open-label study (NCT04646005) recruited patients with recurrent HPV16+ cervical cancer who had previously experienced disease progression after first-line chemotherapy. Patients received a total of 3 doses of peltopepimut-S vaccine on days 1, 29, and 50 and cemiplimab 350 mg every 3 weeks until disease progression or other reason for early discontinuation. Primary endpoint was objective response rate (ORR) per RECISTversion 1.1; secondary endpoints were duration of response (DOR), overall survival (OS), progression-free survival (PFS), and safety.

Results.

Of 113 patients enrolled between June 28, 2021 and May 22, 2023, 80.5 % were white, with a median age of 49.0 years, and 58.4 % had an ECOG PS of 0. Median duration of follow-up was 4.9 months. ORR (95 % CI) per investigator assessment was 16.8 % (9.9-23.7). ORR of patients with squamous cell carcinoma by PD-L1 expression in tumor cells was 15.8 % for patients with PD-L1 < 1 % and 24.1 % for patients with PD-L1 >= 1 %. Median (95 % CI) DOR was 5.6 (3.5-not estimable) months. Median (95 % CI) OS and PFS were 13.3 (10.8-16.3) months and 3.0 (1.7-4.0) months, respectively. Treatment-emergent adverse events (TEAEs) occurred in 92.9 % of patients, the most common being injection-site reaction (38.9 %) and anemia (25.7 %). Six (5.3 %) patients died from a TEAE.

Conclusion.

Cemiplimab+peltopepimut-S vaccine provides similar benefits to cemiplimab monotherapy; patients with higher PD-L1 expression in tumor cells may be more likely to benefit from treatment. (c) 2025 Published by Elsevier Inc.

• Cemiplimab
• Recurrent/metastatic
• Cervical cancer
• Peltopepimut-S vaccine
• HPV16

• All authors: Lorusso, D.; Oaknin, A.; Borges, G.S.; Damian, F.; Ottevanger, N.; Gorp, T. van; Paiva, C.E.; Kroep, J.R.; Kim, Y.M.; Kim, H.S.; Lee, J.K.; Denys, H.; Lalisang, R.; Melo, A.C.D.; Redondo, A.; Reyners, A.K.L.; Mora, P.; Closset, C.; Melief, C.J.M.; Hooftman, L.; Jamil, S.; Boersm, L.; Yoo, S.Y.; Seebach, F.; Lowy, I.; Fury, M.G.; Mathias, M.; Colombo, N.
• Date: 2025-03-27
• Journal: Gynecologic Oncology
• Volume: 196
• Pages: 28 - 35
• DOI: doi:10.1016/j.ygyno.2025.03.019